Nurix Therapeutics, Inc. (NRIX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
NRIX currently has 110M outstanding shares. with limited dilution risk as only 17.3M additional shares (15.7%) are authorized for issuance. The company has significantly diluted shareholders by 61.08% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Apr 08, 2026 |
10-Q filing | 110.1M shares outstanding |
110M | 17M |
| Jan 28, 2026 |
10-K filing | 102.8M shares outstanding |
100M | 17M |
| Jul 09, 2025 |
10-Q filing | 83.9M shares outstanding |
84M | 17M |
| Apr 08, 2025 |
10-Q filing | 83.6M shares outstanding |
84M | 17M |
| Jan 28, 2025 |
10-K filing | 75.9M shares outstanding |
76M | 17M |
| Oct 11, 2024 |
10-Q filing | 72.8M shares outstanding |
73M | 17M |
| Jul 11, 2024 |
10-Q filing | 62.4M shares outstanding |
62M | 17M |
| Apr 10, 2024 |
10-Q filing | 49.2M shares outstanding |
49M | 17M |
| Feb 15, 2024 |
10-K filing | 48.9M shares outstanding |
49M | 17M |
| Oct 12, 2023 |
10-Q filing | 48.5M shares outstanding |
49M | 17M |
| Jul 13, 2023 |
10-Q filing | 48.2M shares outstanding |
48M | 17M |
| Apr 13, 2023 |
10-Q filing | 47.4M shares outstanding |
47M | 17M |
| Feb 09, 2023 |
10-K filing | 48.6M shares outstanding |
49M | 17M |
| Feb 09, 2023 |
POS AM filing: This is a POS AM filing for Nurix Therapeutics, Inc. to offer shares of common stock or preferred stock, debt securities, warrants, subscription rights and/or units up to $450 million aggregate dollar amount. |
47M | 17M |
| Oct 06, 2022 |
10-Q filing | 50.9M shares outstanding |
51M | 17M |
| Jul 07, 2022 |
10-Q filing | 44.9M shares outstanding |
45M | 17M |
| Apr 08, 2022 |
10-Q filing | 45.0M shares outstanding |
45M | 17M |
| Jan 28, 2022 |
10-K filing | 44.7M shares outstanding |
45M | 17M |
| Oct 14, 2021 |
10-Q filing | 44.6M shares outstanding |
45M | 17M |
| Jul 13, 2021 |
10-Q filing | 43.8M shares outstanding |
44M | 17M |
| Apr 13, 2021 |
10-Q filing | 44.3M shares outstanding |
44M | 17M |
| Mar 02, 2021 |
S-1 filing: This is an S-1 filing for an initial public offering of common stock. |
39M | 17M |
| Feb 16, 2021 |
10-K filing | 38.9M shares outstanding |
39M | 13M |
| Oct 14, 2020 |
10-Q filing | 38.9M shares outstanding |
39M | 13M |
| Jul 23, 2020 |
S-1/A filing: This is an S-1/A filing for an IPO of common stock with an option to purchase additional shares, to fund the further development of NX-2127, NX-1607 and other preclinical programs, conduct research, fund the further development of our technology platform, broaden our pipeline of product candidates and for working capital and general corporate purposes. |
37M | 13M |
| Jul 20, 2020 |
S-1/A filing: This is an S-1/A filing for an initial public offering of common stock with an option to purchase additional shares. |
35M | 10M |
| Jul 02, 2020 |
S-1 filing: This S-1 filing outlines a proposed offering of common stock, with an option for underwriters to purchase additional shares, and details the company's financial position, use of proceeds, and associated risk factors. |
11M | 0 |